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Cardiovascular Diabetology
Open Access

Proteomic alterations of HDL in youth
with type 1 diabetes and their associations
with glycemic control: a case–control study
Evgenia Gourgari1* , Junfeng Ma2,3, Martin P. Playford4, Nehal N. Mehta4, Radoslav Goldman3, Alan T. Remaley5
and Scott M. Gordon6,7

Abstract
Background: Patients with type 1 diabetes (T1DM) typically have normal or even elevated plasma high density
lipoprotein (HDL) cholesterol concentrations; however, HDL protein composition can be altered without a change in
cholesterol content. Alteration of the HDL proteome can result in dysfunctional HDL particles with reduced ability to
protect against cardiovascular disease (CVD). The objective of this study was to compare the HDL proteomes of youth
with T1DM and healthy controls (HC) and to evaluate the influence of glycemic control on HDL protein composition.
Methods: This was a cross-sectional case–control study. Blood samples were obtained from patients with T1DM and
HC. HDL was isolated from plasma by size-exclusion chromatography and further purified using a lipid binding resin.
The HDL proteome was analyzed by mass spectrometry using label-free SWATH peptide quantification.
Results: Samples from 26 patients with T1DM and 13 HC were analyzed and 78 HDL-bound proteins were measured.
Youth with T1DM had significantly increased amounts of complement factor H related protein 2 (FHR2; adjusted
P < 0.05), compared to HC. When patients were analyzed based on glucose control, several trends emerged. Some
proteins were altered in T1DM and not influenced by glycemic control (e.g. FHR2) while others were partially or
completely corrected with optimal glucose control (e.g. alpha-1-beta glycoprotein, A1BG). In a subgroup of poorly
controlled T1DM patients, inter alpha trypsin inhibitor 4 (ITIH4) was dramatically elevated (P < 0.0001) and this was
partially reversed in patients with optimal glucose control. Some proteins including complement component C3
(CO3) and albumin (ALB) were significantly different only in T1DM patients with optimal glucose control, suggesting a
possible effect of exogenous insulin.
Conclusions: Youth with T1DM have proteomic alterations of their HDL compared to HC, despite similar concentration of HDL cholesterol. The influence of these compositional changes on HDL function are not yet known. Future
efforts should focus on investigating the role of these HDL associated proteins in regard to HDL function and their
role in CVD risk in patients with T1DM.
Trial registration NCT02275091
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Introduction
Patients with type 1 diabetes (T1DM) are at increased
risk for cardiovascular disease [1]. This risk starts early
in life as there is evidence of subclinical cardiovascular
disease (CVD) in youth with T1DM [2]. The primary risk
factors that have been attributed to CVD in this population include poor glycemic control, hypertension, obesity, and dyslipidemia [1, 3]. Dyslipidemia, characterized
by non-HDL cholesterol > 130 mg/dL was found in 27.7%
and low HDL < 35 mg/dL in only 3.4% of a large cohort
of 682 children with T1DM [4]. In the SEARCH study,
among 512 youth with T1DM and 188 healthy controls,
the prevalence of low HDL < 35 mg/dL was 10.3%, 7.6%
and 5% among healthy children and youth with T1DM
and optimal or suboptimal control, respectively [5]. In
general, low HDL levels in patients with T1DM is not as
frequent as other types of dyslipidemia and the HDL profile can often even be favorable in patients with T1DM.
However, despite the normal HDL cholesterol, the function of HDL can be impaired in some patients with
T1DM [6–8]. The primary cardioprotective functions of
HDL include the following: (i) prevention of the oxidation of LDL (ii) cholesterol efflux from the vessel wall and
transport of cholesterol to the liver and (iii) anti-inflammatory function [9].
Alterations in the protein composition of HDL can
affect its protective functions [7, 10]. For example, adults
with T1DM and low levels of the protein apolipoprotein A-I (apoA-I) on the HDL particles were more likely
to develop CVD [7]. Adult patients with T1DM and
subclinical atherosclerosis have decreased levels of the
potent antioxidant protein paraoxonase-3 (PON3) and
PON3 concentration correlates with the anti-inflammatory function of HDL [9]. HDL proteome studies done in
patients with type 2 diabetes (T2DM) have found alterations of HDL proteins linked to increased CVD risk [11,
12].
The influence of T1DM on the HDL proteome in youth
with T1DM has not been reported. Our goal was to test
the hypothesis that youth with T1DM have protein alterations on HDL that could play a role in modifying HDL
function and contribute to an increased risk for CVD.
In this study, SWATH mass spectrometry was used for
label-free relative quantification of the HDL proteome.
The protein composition of HDL was compared between
youth with T1DM and healthy controls (HC) and the
effect of glycemic control on HDL bound proteins was
evaluated.
Methods
Study participants

All participants were enrolled in the clinical protocol
“Identifying children with type 1 diabetes at high risk
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for CVD” (Clinical Trials Number: NCT02275091) that
was approved by the Georgetown-Howard Universities Center for Clinical and Translational Science Institutional Review Board (IRB). Written informed consent
was obtained from all parents of pediatric patients and
all adult patients and assent was obtained from all children < 18 years old. Youth with T1DM and healthy controls between the ages of 12 and 21 years were eligible
for participation. Subjects on lipid lowering medications
were excluded from participation.
Recruitment of study participants was done by sending IRB approved letters to the patients with T1DM
who are followed at the Pediatric Endocrine Divisions
of Georgetown University (GU) and Children’s National
Health System in Washington, DC. Healthy controls were
recruited mainly by sending letters to families of children
who had their well-child visits in the pediatric clinic of
GU.
A research nurse conducted the anthropometric measurements and the BMI z-score was calculated using the
CDC charts. Lipoprotein concentrations were measured
using Liposcience NMR spectroscopy at the National
Institutes of Health Clinical Center as previously
described [13].
Proteomics experiments

Preparation of samples for proteomics experiments was
done following a number of steps as previously described
[14, 15] and briefly summarized below: (1) purification
of HDL from serum by size-exclusion chromatography;
(2) pooling of all HDL containing fractions; (3) application of pooled HDL to lipid binding resin; (4) washing
of HDL on resin to remove contaminating proteins; (5)
trypsin digest of HDL on resin (overnight); (6) washing of the resin to collect tryptic peptides; (7) reduction
and carbamidomethylation (DTT and iodoacetamide,
respectively); and (8) sample desalting using ZipTips.
The samples were dried down for proteomics analysis by
using a nanoAcquity UPLC coupled with a TripleTOF
6600 mass spectrometer. First, we established a protein
library of all HDL proteins detectable by mass-spectrometry (MS) for the analysis of a sample pool from all the
subjects (with equal amount of proteins combined). The
pooled sample was analyzed with 4 consecutive runs
data in data dependent acquisition (DDA) mode. We
then ran each sample individually via label-free SWATH
data independent acquisition (DIA) to quantify each of
these proteins in the samples. Specifically, peptides in
each sample were dissolved into 20 µL of 0.1% formic
acid. For spectra library generation, the pooled sample
was loaded onto a C18 Trap column (Waters Acquity
UPLC Symmetry C18 NanoAcquity 10 K 2G V/M, 100 A,
5 μm, 180 μm × 20 mm) at 15 µL/min for 4 min. Peptides
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were then separated with an analytical column (Waters
Acquity UPLC M-Class, peptide BEH C18 column, 300
A, 1.7 μm, 75 μm × 150 mm) which was temperature
controlled at 40 °C. The flow rate was set as 400 nL/
min. A 60-min gradient of buffer A (2% ACN, 0.1% formic acid) and buffer B (0.1% formic acid in ACN) was
used for separation: 1% buffer B at 0 min, 5% buffer B at
1 min, 45% buffer B at 35 min, 99% buffer B at 37 min,
99% buffer B at 40 min. The gradient went back to 1%
buffer B to equilibrate the column for 20 min. The TripleTOF 6600 mass spectrometer was operated with an
ion spray voltage of 2.3 kV, GS1 5 psi, GS2 0, CUR 30 psi
and an interface heater temperature of 150 °C. The mass
spectra were recorded with Analyst TF 1.7 software in
the data dependent acquisitions (DDA) mode. Each cycle
consisted of a full scan (m/z 400–1800) and fifty (IDAs)
(m/z 100–1800) in the high sensitivity mode with a 2+
to 5+ charge state. Rolling collision energy was used. For
SWATH acquisition, each of the samples was injected
individually into the same NanoUPLC-MS/MS system (same settings as above) but acquired by repeatedly
cycling through 32 consecutive 25-Da precursor isolation
windows, generating time-resolved fragment ion spectra
for all the analytes detectable within the 400–1200 m/z
precursor range.
Proteomics data analysis

For spectra library generation, raw mass spectra files
after DDA acquisition of the pooled sample were submitted for combined searches using Protein Pilot version 5.0
software (Sciex) utilizing the Paragon and Progroup algorithms [16] and the integrated false discovery rate (FDR)
analysis function [17]. MS/MS data were searched against
the NCBI Homo Sapiens of the Uniprot-Sprot database
containing 20,316 entries (downloaded on June 2, 2015).
Trypsin was selected as the enzyme and carbamidomethylation was set as a fixed modification on cysteine. Variable peptide modifications included only methionine (M)
oxidation. Other search parameters included instrument
(TripleTOF 6600), ID Focus (Biological modifications),
search effort (Thorough), false discovery rate (FDR)
analysis (Yes), and user modified parameter files (No).
The proteins were inferred based on the ProGroupTM
algorithm associated with the ProteinPilot software. The
detected protein threshold in the software was set to the
value which corresponded to 1% FDR. Peptides were
defined as redundant if they had identical cleavage site(s),
amino acid sequence, and modification.
For the label-free SWATH quantification, data from
each sample was pre-processed by PeakView 2.1 (Sciex),
with the default settings: (1) peptide filter: # of peptides
per protein: 6; # of transitions per peptide: 6; peptide confidence threshold: 99%; FDR threshold: 1%; (2) extracted
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ion chromatogram (XIC) Options: XIC extraction window (min): 5; XIC width (ppm): 75. Retention time was
calibrated by selecting 6 peptides with retention time
across the whole HPLC gradient. Peak of each transition
produced was then manually checked and curated, with
only transitions detected in all samples and showing signal to noise (S/N) > 10 chosen for peak area calculation.
The peptide response was calculated as the sum of all ion
intensity for all curated transitions. The sum of response
of all curated peptides in each protein was used for protein level quantification (Additional file 1: Table S1). The
intensity of proteins was then normalized to the total ion
intensity of each sample, with the ratio of protein representing the protein level in each sample (Additional file 2:
Table S2).
Cholesterol efflux analysis

To determine whether any of the proteins of interest are
related to changes in the cholesterol efflux function of
HDL, we measured HDL efflux capacity as previously
described by our group [8]. In summary, HDL cholesterol
efflux capacity assays were performed using the murine
macrophage cell line, J774, based on published methods,
[18–20]. Briefly, 3 × 105 J774 cells/well were plated and
radiolabeled with 2 µCi of 3H-cholesterol/mL for 24 h.
ATP-binding cassette transporter A1 (ABCA1) was upregulated by means of a 16-h incubation with 0.3 mmol/L
8-(4-chlorophenylthio)-cAMP. ApoB-depleted plasma
(2.8%) was added to the efflux medium for 4 h. Liquid
scintillation counting was added to quantify the efflux of
radioactive cholesterol from the cells. Efflux was calculated using the following formula: (µCi of 3H-cholesterol
in media containing 2.8% apoB-depleted subject plasmaµCi of 3H-cholesterol in plasma-free media/µCi of
3
H-cholesterol in media containing 2.8% apoB-depleted
pooled control plasma-µCi of 3H-cholesterol in pooled
control plasma-free media). The pooled plasma was
obtained from five healthy adult volunteers. All assays
were performed in duplicates.
Statistical analysis

Ion intensity data for each protein was tested for normality using the Shapiro–Wilk test (SigmaPlot 13.0). All protein ion intensity measurements were log10 transformed
prior to analysis. To identify proteins with differential
abundance between healthy control and T1DM groups
we used two approaches: (A) Student’s t test was used on
individual proteins, without correction for multiple comparisons. In proteomics data sets, common methods of
adjustment for multiple comparisons testing often result
in a high occurrence of false negatives [21]. To reduce
the risk of omitting true positive hits from this analysis,
these results were initially screened using more relaxed
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statistical criteria with a P value threshold of 0.05 without corrections for multiple comparisons. (B) To evaluate
the data with consideration for multiple testing correction, we used the two stage step up false discovery rate
method of Benjamini, Krieger and Yekutieli with a Q
value cutoff of 5%. The ion intensity dataset included one
missing data point (out of 3042 observations). The missing data point was ignored in subsequent calculations.
Fold-change was calculated as the ion intensity in T1DM
divided by the same protein’s intensity in the healthy control group. Linear regression and ANOVA analyses were
performed under described parameters using GraphPad
Prism 7 software.

Results
Study population

We analyzed the HDL proteome in 26 patients with
T1DM and 13 HC (Table 1). Patients were matched for
age, sex, BMI, and clinical lipid measures. The average
duration of diabetes was 2.9 ± 1.1 years in the T1DM
group and the average HbA1c was 8.9 ± 1.8% in the
T1DM and 5.3 ± 0.3% in the HC, P ≤ 0.001.
HDL proteome analysis

We developed a library for MS-based label-free quantitation of HDL-bound proteins, using a subset of samples
from each study group. This approach quantified 78 proteins that are present in HDL fractions in both T1DM
and HC (matched with 229 peptides and 1142 transitions; > 95% confidence) after manual curation (i.e., only
transitions showing S/N > 10 were selected for quantification) (Additional file 1: Table S1).
Analysis of the HDL proteome in all participants
using an unadjusted t-test revealed 8 proteins that were

potentially altered among the patients with T1DM and
HC. Six of these proteins were elevated in HDL of youth
with T1DM and two of them were decreased (Fig. 1).
Youth with T1DM had significantly higher protein levels of alpha-1B-glycoprotein (A1BG; P = 0.003), apolipoprotein A-IV (APOA4; P = 0.037), complement factor H
(CFAH; P = 0.0488), factor H related protein 2 (FHR2;
P = 0.0005), inter-alpha trypsin inhibitor 4 (ITIH4;
P = 0.013), peptidoglycan recognition protein 2 (PGRP2;
P = 0.017) and lower levels of albumin (ALBU; P = 0.027)
and complement C3 (CO3; P = 0.015) compared to HC.
When these results were analyzed with more strict statistical approach by applying a false discovery rate threshold of 5%, only one protein was identified as statistically
significant, FHR2 (P = 0.039).
To determine if HDL-bound proteins correlate with
glycemic control, linear regression analysis was used to
evaluate the relationships between measured proteins
and HbA1c. Of those proteins potentially altered by type I
diabetes status, A1BG (r2 = 0.23, adjusted P = 0.0152) was
significantly associated with HbA1c (Table 2). To examine the effect of glycemic control in patients, we divided
the T1DM cohort into poorly controlled (HbA1c > 7.6%,
n = 15) and well-controlled (HbA1c ≤ 7.6%, n = 11)

Table 1 Clinical characteristics of heavy control and T1DM
patients
Healthy controls Type 1 diabetes P value
n

13

26

–

Age (years)

16.8 ± 1.4

16.9 ± 1.9

0.99

18 (69%)

–

0.1 ± 1.0

0.4 ± 0.1

0.79

–

2.9 ± 1.1

–

Female sex, n (%)
BMI z score
HbA1c %
Diabetes duration
hsCRP
HDL cholesterol (mg/
dL)

11 (84%)
5.3 ± 0.3

0.33 ± 0.2

59.0 ± 12.0

8.9 ± 1.8

< 0.0001

1.9 ± 3.5

0.60

59.7 ± 8.6

0.99

LDL cholesterol (mg/
dL)

60.5 ± 28.8

72.6 ± 21.9

0.60

Triglyceride (mg/dL)

81.6 ± 34.5

81.7 ± 36.3

0.99

P values are derived from t tests with Holm–Sidak correction for multiple
comparisons

Fig. 1 The HDL proteome is altered in youth with type 1 diabetes.
HDL was isolated from youth with T1DM and healthy controls
then proteome composition was analyzed by mass spectrometry
to quantify 78 HDL-bound proteins. This volcano plot displays
the differences in protein abundance detected between the
healthy controls (HC) and T1DM subjects. Each point represents
one of the 78 detected proteins. Green points are proteins with
positive fold change (i.e. increase in T1DM) and red points are
negative fold changes. Horizontal dotted lines indicate statistical
thresholds for a false discovery rate (FDR) of 5% by the method of
Benjamini, Krieger and Yekutieli or a P-value < 0.05 calculated using
two-tailed t-test without adjustment for multiple comparisons.
A1BG alpha-1B-glycoprotein, APOA4 apolipoprotein A-IV, FHR2
factor-H related protein 2, ITIH4 inter-alpha trypsin inhibitor 4,
PGRP2 peptidoglycan recognition protein 2, ALBU albumin, CO3
complement C3, CFAH complement factor H
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Table 2 Linear regression of HbA1c with HDL-bound
proteins
Protein
A1BG
FHR2
PGRP2
ITIH4
CFAH
APOA4
CO3
ALBU

Slope

R square

P value

Adjusted P

0.026 ± 0.008

analysis was performed using the PANTHER overrepresentation analysis with Fisher’s Exact test and FDR correction [23]. This analysis compares the frequency of protein
class assignments within a list of proteins to the frequency
of those function classes in the entire human proteome.
The HDL-associated proteins altered by T1DM contains
a significant enrichment of protease inhibitor (P = 0.0076,
FDR adjusted) and serine protease inhibitor (P = 0.023,
FDR adjusted).

0.23

0.0019

0.015

0.076 ± 0.031

0.14

0.020

0.16

0.039 ± 0.021

0.09

0.064

0.51

0.024 ± 0.013

0.09

0.069

0.55

0.031 ± 0.017

0.08

0.074

0.59

0.013 ± 0.008

0.07

0.10

0.81

− 0.014 ± 0.011

0.04

0.20

1.60

Cholesterol efflux analysis

− 0.008 ± 0.009

0.02

0.41

3.26

As an indicator of HDL function, cholesterol efflux capacity (CEC) to apoB depleted plasma was measured. No differences in CEC were detected between the HC and T1DM
groups (Additional file 3: Figure S1). Additionally, proteins
influenced by T1DM status did not correlate with CEC.

P values adjusted for multiple comparisons by Bonferroni method

subjects. Comparison of proteins levels among the three
subgroups revealed four different trends: (1) the protein is elevated in patients with T1DM and not affected
by glycemic control (FHR2; Fig. 2a). (2) The protein is
elevated in T1DM and partially returns to normal with
glycemic control (A1BG; Fig. 2b). (3) The protein only
differs in patients with well-controlled T1DM, suggesting possible effect of exogenous insulin (CO3 and ALBU;
Fig. 2c, d). (4) The proteins are not affected by T1DM
control status (ITIH4, PGRP2, APOA4, CFAH; Fig. 2e–
h). A bimodal distribution of ITIH4 was apparent in subjects with poorly controlled T1DM (Fig. 2e). To further
examine this effect, we isolated these two subpopulations
and reanalyzed the relationship among the three groups.
ITIH4 in subjects with poorly controlled T1DM and
low ITIH4 was not different compared to HC (Fig. 3a).
However, the poorly controlled T1DM subjects with
high ITIH4 had significantly greater ITIH4 than HC and
well-controlled T1DM subjects (Fig. 3b). Linear regression analysis of the cohort with the poorly controlled low
ITIH4 subjects removed revealed a striking correlation
between HDL-bound ITIH4 and HbA1c (Fig. 3c). Patient
data including sex, BMI, hsCRP, or duration of diabetes
did not correlate with ITIH4 high/low status.
Overall, five proteins were determined to be influenced
by T1DM and glycemic control: CO3, ITIH4, A1BG, FHR2,
and ALBU. These proteins were annotated with known
functions using PANTHER protein classifications (version
14.0) (Fig. 4) [22]. The most represented protein classes
are protease inhibitor (3/5), serine protease inhibitor (2/5),
and complement component (2/5). Function enrichment

Discussion
This report describes, for the first time, proteomic alterations of HDL in a cohort of young adults with T1DM. We
have identified several HDL-bound proteins that are significantly affected in patients with T1DM. We observed three
clear trends in those affected proteins. FHR2 was increased
in T1DM and not corrected by glucose control. This may
suggest that this is caused by some consequence of the
underlying condition and not circulating glucose levels.
A1BG and ITIH4 were increased in T1DM and partially
corrected by glucose control. Finally, CO3 and ALB are
decreased in T1DM patients with well-controlled glucose.
This may suggest the administration of insulin is influencing the association of these proteins with HDL.
Gene ontology analysis using PANTHER protein classifications revealed a significant enrichment of proteins with
protease inhibitor function, particularly serine protease
inhibitors. This indicates that the effect of T1DM on the
HDL proteome may specifically influence the protease regulator activity of HDL. Protease regulator activity on HDL
has been previously suggested to play an important role
in atherosclerotic cardiovascular disease [24]. The following paragraphs discuss some potential roles for each of the
affected proteins in HDL function and CVD risk.
FHR2, is a complement factor H (CFAH) related protein that resembles structurally and immunologically the
complement factor H. While the complement pathway
is a critical component of innate immunity, inappropriate
complement activation has been linked to inflammation,

(See figure on next page.)
Fig. 2 Effects of glycemic control on HDL-bound proteins. T1DM participants were separated into those with either “poor” or “optimal” glycemic
control and levels of HDL-bound proteins detected by mass spectrometry were compared with healthy controls (HC) by one-way ANOVA with
Dunnett’s correction for multiple comparisons. a FHR2 factor-H related protein 2; b A1BG alpha-1B-glycoprotein; c CO3 complement C3; d ALBU
albumin; e ITIH4 inter-alpha trypsin inhibitor 4; f PGRP2 peptidoglycan recognition protein 2; g APOA4 apolipoprotein A-IV; h CFAH complement
factor H *P < 0.05; **P < 0.01; n.s. indicates not statistically significant
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Cytokine

Transfer/carrier protein

Membrane-bound signaling molecule

Immunoglobulin receptor superfamily

Complement component

Serine protease inhibitor

Protease inhibitor

Fig. 3 ITIH4 displays a unique bimodal distribution in T1DM subjects with poor glycemic control. a, b T1DM subjects with poor glycemic control
were separated into ITIH4-Low and ITIH4-High groups and compared separately with the other groups by one-way ANOVA with Dunnett’s
correction for multiple comparisons. c Linear regression analysis of entire cohort with T1DM poor (ITIH4-Low) subjects removed. *P < 0.05; **P < 0.01;
***P < 0.001; n.s. indicates not statistically significant. ITIH4 inter-alpha trypsin inhibitor 4

CO3
ITIH4
A1BG
FHR2
ALBU

PANTHER protein classifications of the HDL-associated proteins
altered in T1DM subjects.

Fig. 4 Functional classifications of HDL-associated proteins affected
by T1DM. PANTHER protein classification system was used to identify
known functions of each of the proteins altered by T1DM in this
study. CO3 complement C3, ITIH4 inter-alpha trypsin inhibitor 4, A1BG
alpha-1B-glycoprotein, FHR2 factor-H related protein 2, ALBU albumin

diabetes, insulin resistance, atherosclerosis, and cardiometabolic diseases [25, 26]. Complement factor H is an
important regulatory protein and prevents tissue damage
from inappropriate complement activation [27]. Recently,
it was shown that factor H binds to ApoE on HDL and
this plays a role in regulating complement activation [28].

Furthermore, CFAH presence has also been linked with
decreased insulin production from rat pancreatic cells
and it may play a role in the pathogenesis of diabetes [27].
Whether the increased FHR2 in HDL of T1DM patients
is related to the pathogenesis of T1DM remains to be
explored. FHR2 has been previously detected on lipoproteins and it is thought to facilitate the adhesive response
of neutrophils to lipopolysaccharides [27]. It is also possible that complement factor H and complement factor H
related proteins (such as FHR2) play a role in lipid transport and regulate lipid homeostasis [29]. The mechanism
by which CFAH and FHR2 interact to regulate HDL function in diabetes requires further investigation.
A1BG, alpha-1-B glycoprotein, belongs to the immunoglobulin family and its function is largely unknown [30,
31]. A1BG was found to be overexpressed in tissues of
pancreatic ductal adenocarcinoma and liver cancer cell
lines [30], while it was not detected in normal pancreatic tissue and hence could be useful as a tumor marker.
A1BG was also reported to be elevated in the urine of
normoalbuminuric patients with T1DM when compared
to healthy controls; however, the urine levels of this
protein did not correlate with HbA1c or urine microalbumin [31]. Whether this protein could serve as a urine
biomarker of early diabetic kidney disease remains to be
examined. Interestingly, pharmacogenomic studies have
shown that polymorphisms in the A1BG gene can play a
role in cardiovascular outcomes of patients treated with
antihypertensive medications [32].
ITIH4, inter-alpha-trypsin inhibitor heavy chain H4,
belongs to the liver-restricted serine protease inhibitor
family. It is highly expressed in liver development and
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low levels have been found in hepatocellular and ovarian
cancer [33, 34]. ITIH4 is elevated in urine of patients with
T2DM and microalbuminuria and could possibly serve as
a biomarker for diabetic kidney disease [35]. ITIH4 was
also found to be downregulated after a very low caloric
diet in patients with T2DM, possibly representing a biomarker of metabolic improvement [36].
We were unable to identify a clinical basis for the
bimodal distribution of ITIH4 in the poorly controlled
T1DM cohort. Using logistic regression analysis, high
vs low ITIH4 grouping does not appear to correlate with
age, sex, BMI, hsCRP, or duration of diabetes. However,
the high ITIH4 group, which made up 66% of the poorly
controlled cohort displayed a robust elevation compared
to HC that, similar to A1BG, was partially corrected with
glycemic control. These results suggest that better glycemic control could reverse the changes associated with
overexpression of A1BG and ITIH4 on HDL. The fact
that some protein alterations can be corrected by glycemic control and others cannot indicates that these HDL
proteome effects may be mediated by different mechanistic pathways. Future studies could examine how glycemic
control alters HDL structure and function and explore
novel mechanisms to improve CVD risk in T1DM.
ALBU, albumin, is the most abundant protein in the
plasma and binds to electrolytes, hormones, fatty acids
and drugs. Relatively low serum albumin has also been
used as a marker of increased mortality from CVD [37,
38]. Serum albumin has been found to be positively correlated with HDL and total cholesterol, and it is possible
that low serum albumin reflects abnormalities in lipid
metabolism and function [39]. Interestingly, glycated
albumin was shown to decrease the anti-inflammatory
function of HDL and impair the reversed cholesterol
transport function, contributing to the development of
CVD in patients with diabetes [40]. Whether the low
albumin on HDL we found in our patients with T1DM
reflects an imbalance between glycosylated and non-glycosylated forms of albumin requires further study.
CO3, complement factor 3, is produced by macrophages and plays a key initiating role in the activation of complement on the vascular endothelium,
which triggers an inflammatory response, creating a
vessel wall that is prone to atherosclerosis and increasing CVD risk [26]. CO3 has been previously detected
on HDL [10, 41]. Vaisar et al. reported multiple complement regulatory proteins on HDL fractions [41].
Interestingly, in their study, subjects with cardiovascular disease had significantly elevated levels of CO3 on
HDL fractions [41]. Others have shown that increased
CO3 on HDL of patients with CVD, psoriasis and
rheumatoid arthritis is linked to decreased cholesterol
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efflux [10, 42, 43]. Additionally, HDL-bound CO3 has
been correlated with increased non-calcified plaque
burden in patients undergoing coronary CT angiography [44]. The current study found lower CO3 in T1DM
compared to HC (although statistically significant only
in the “well-controlled” glycemic cohort), which suggests a protective effect of insulin given the evidence
in literature. This could represent a protective role of
HDL against CVD in T1DM subjects during the early
stages of disease.
Both ALBU and CO3 were significantly lower only
in the group of T1DM with optimal control compared
to HC, suggesting that perhaps higher doses of insulin may play a role in altering their values. Insulin can
increase the transcapillary escape of albumin as well as
the urinary excretion of albumin and whether the lower
albumin and CO3 on HDL could be secondary to these
mechanisms requires further investigation [45, 46].
Strengths of our study include that this is a well-characterized cohort of youth with T1DM, with optimal
and suboptimal glycemic control, along with detailed
HDL proteome data. The combination of two-step sizeexclusion chromatography and lipid interaction based
HDL purification and SWATH-MS provides sensitive
and robust label-free proteomic quantitation for multiple clinical samples. Limitations include the small
sample size and lack of full functional studies for each
protein of interest. Our goal for this project was to provide an initial characterization of the proteomic differences in HDL composition between youth with T1DM
and HC and identify associations with glycemic control. Future studies will further investigate the functional roles of the identified proteins that differed on
HDL from T1DM patients.
Our group has previously published differences in the
cholesterol efflux values between T1DM and HC in a
larger cohort [8], but in this particular subset of participants we did not detect differences in cholesterol
efflux, potentially because of the smaller sample size,
the well-controlled status in half of the T1DM participants and their short diabetes duration. There were no
significant correlations between the specific proteins of
interest and cholesterol efflux. The lack of a group wide
effect on HDL’s cholesterol efflux capacity, is not necessarily surprising considering that the HDL-cholesterol
levels are not different in this cohort and the protein
changes detected here do not include proteins known
to influence efflux (e.g. apoA-I, serum amyloid A, etc.)
[44, 47]. Based on our functional classification analysis,
it seems likely the influence of T1DM on HDL may be
more strongly tied to HDL’s roles in protease regulation
and inflammation [24].
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Conclusions
In summary, we found altered protein composition of
HDL in youth with T1DM compared to HC by combining size-exclusion chromatography-based HDL purification and SWATH-MS-based label-free proteomic
quantitation. The specific proteomic changes suggest a
possible connection with increased risk for cardiovascular disease, via multiple pathways relevant to known
functions associated with the affected proteins. Future
studies should examine the specific role of each protein
on altering known functions of HDL such as anti-inflammatory activity, cholesterol efflux capacity, and prevention of oxidation of LDL or the exploration of novel
HDL functions. Larger epidemiologic studies could also
examine the association of the altered HDL proteins with
cardiovascular events. Finally, the association of glycemic control with some of these HDL associated proteins
suggests the possibility that better glycemic control could
reverse compositional abnormalities of HDL and potentially decrease CVD risk by restoring HDL function.
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